News from

Cancer Research

Reset All Filters
426 Results
Brain tumor organoids accurately model patient response to CAR T cell therapy
Microscopic view of a glioblastoma organoid.

A patient-derived glioblastoma organoid treated with dual-target CAR-T cells. T cells (magenta) infiltrate the tumor organoid and kill tumor cells (blue; yellow indicates dying cells).

(Image: Yusha Sun and Xin Wang from the laboratories of Guo-li Ming and Hongjun Song)

Brain tumor organoids accurately model patient response to CAR T cell therapy

Lab-grown tumors respond to cell therapy the same as tumors in the patients’ brains, according to researchers at Penn Medicine.

Kelsey Geesler

2 min. read

Easing patient fears of radiation treatment, via virtual reality
People holding VR headsets at a display table.

Peter Decherney (far left), professor of cinema and media studies in the School of Arts & Sciences, is the instructor of the undergraduate Virtual Reality Lab spring course.

(Image: Courtesy of Penn Medicine News)

Easing patient fears of radiation treatment, via virtual reality

Before their first dose of radiation, cancer patients can shadow another patient’s treatment and get a private behind-the-scenes tour with the team members via virtual reality.

From Penn Medicine News

White House names Abramson Cancer Center neuro-oncologist a Cancer Moonshot Scholar
Richard Phillips.

Richard Phillips is one of 11 Cancer Moonshot Scholars chosen for innovative cancer research. He will specialize in tumor epigenetics, researching how changes to DNA can impact the development of cancer cells in children and young adults.

(Image: Dan Burke)

White House names Abramson Cancer Center neuro-oncologist a Cancer Moonshot Scholar

Richard E. Phillips, chief of the division of Neuro-Oncology and an assistant professor of neurology, is among 11 scholars included in this year’s cohort, who will support cancer research and innovation across the country. 

Kelsey Geesler

Understanding the cellular mechanisms driving solid tumors’ robust defense system
A 3D rendering of the tumor microenvironment with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment normal cells, molecules, and blood vessels.

In a collaborative interdisciplinary study, Michael Mitchell of the School of Engineering and Applied Science, Wei Guo of the School of Arts & Sciences, and Drew Weissman of the Perelman School of Medicine show that solid tumors can block drug-delivery mechanisms with a “forcefield-like” effect but certain genetic elements that can effectively “shut down” the forcefield. Their findings hint at new targets for delivering cancer treatments that use the body’s immune system to fight tumors.

(Image: iStock / CIPhotos)

Understanding the cellular mechanisms driving solid tumors’ robust defense system

Researchers from Penn have identified a “forcefield-like” defense system in solid tumors and the genetic elements that can switch it off.